By targeting the vascular endothelial growth factor (VEGF) and EGFR pathways, anti-angiogenic agents and EGFR inhibitors have revolutionized the treatment landscape for metastatic colorectal cancer. This evidence concerns the gene VEGFA and metastatic colorectal cancer.